查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球年齡相關性黃斑變性市場
市場調查報告書
商品編碼
1143388

2022-2029 年全球年齡相關性黃斑變性市場

Global Age Related Macular Degeneration Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

到 2021 年，與年齡相關的黃斑變性市場規模估計為 98.4 億美元，在預測期間（2022-2029 年）以 6.90% 的複合年增長率增長。

年齡相關性黃斑變性包括治療急性和慢性傷口的產品，例如潰瘍、燒傷和手術後傷口。薄膜和泡沫敷料、水凝膠、藻酸鹽和水膠體等產品可將水分保留在傷口中，以促進癒合而不阻塞傷口。這個市場為慢性傷口患者提供了一種解決方案，提供易於獲得且價格合理的產品，方便他們使用。與年齡相關的黃斑變性管理市場報告還涵蓋了各種競爭技術，例如先進的傷口敷料技術、有害壓力傷口治療 (NPWT)、生物製劑/生物活性產品和高壓氧治療設備。

市場動態

市場增長的主要驅動力是全球與年齡相關的眼病患病率不斷上升、老年人口不斷增長、技術進步以及治療報銷帶來的好處。

全球與年齡相關的眼病增加和老齡化社會的進步預計將推動市場增長

根據世界衛生組織的數據，2020 年全球約有 1.96 億人將受到老年性黃斑變性的影響，其中超過 1040 萬人將遭受中度至重度視力障礙。此外，聯合國經濟和社會事務部的數據顯示，到 2020 年，65 歲及以上的人口將達到約 7.27 億。但是，據說到2050年老年人口將增加約200萬。目前，只有少數藥物，主要是抗 VEGF 藥物，被批准用於治療老年性黃斑變性。抗VEGF藥物需要反複眼內註射，不方便、繁重，導致治療不依從。為了克服這一挑戰，主要參與者正在開髮長效抗 VEGF 藥物和促進持續給藥的玻璃體植入物。 Beov 和 Babismo 等長效抗 VEGF 藥物的推出預計將在預測期內促進市場增長。

高昂的治療成本是阻礙市場增長的主要因素之一

這個市場的主要製約因素是治療成本。一次注射費用高達 775.3 美元，大多數患者每年需要大約 8 次注射。然而，在幾項研究中，與雷珠單抗和阿柏西普 IVAN 試驗（由英國衛生部資助）相比，第三種非常相似的藥物貝伐單抗 (Avastin) 單次注射成本僅為 27.14 美元。顯示具有相似的效果。因此，貝伐單抗在美國和澳大利亞等其他國家被廣泛用於 AMD，在英國被廣泛用於導致新生血管形成的其他疾病（如糖尿病視網膜病變）。然而，除了在英國沒有獲得治療 AMD 的許可外，這種更便宜的替代方案並未在 NHS 中廣泛用於治療這種常見疾病。

COVID-19 影響分析

在 COVID-19 流行初期，AMD 治療的錯過或延遲隨訪導致不依從性，從而對市場產生負面影響。例如，2020 年 7 月，霍夫曼羅氏 (Hoffman-Roche) 的 AMD 藥物 Lucentis 第二季度銷售額增長緩慢，同比增長 4.01 億美元。

全球年齡相關性黃斑變性市場 - 行業分析

全球年齡相關性黃斑變性市場基於波特五力、監管分析、報銷分析、供應鏈分析、定價分析和技術進步等各種行業因素對市場進行了深入分析。 .

細分分析

濕性 AMD 細分市場有望在全球老年性黃斑變性市場佔據最大市場份額

濕性 AMD 病例佔全球因黃斑變性導致的所有視力喪失病例的 10-15% 以上。 Lucentis、Eilea 和 Beov 是治療濕性老年性黃斑變性的有效藥物。諾華的長效抗 VEGF 藥物 Beov 於 2019 年 10 月獲得美國 FDA 批准。然而，該藥物具有不利的副作用，例如視網膜血管炎，這將限制其更廣泛的吸收。

此外，2021 年 9 月，Biogen 和三星 Bioepis 宣布，品牌名稱為“BYOOVIZ”的 Lucentis 生物仿製藥版本將用於濕性 AMD、近視脈絡膜新生血管和視網膜靜脈阻塞的測試。已獲得美國 FDA 批准作為治療劑在美國，由於申請了附加保護證書，於2022年6月發布。此外，包括英國在內的歐盟國家已於2021年8月獲得批准。

按地區分析

北美在全球老年性黃斑變性市場中佔有最大的市場份額

全球老年性黃斑變性市場由北美主導，預計在預測期內將保持其地位。根據美國眼科學會的數據，北美約有 1500 萬人患有 AMD。此外，在 Beaver Dam 眼科研究中，進行性 ARMD 的患病率為 1.6%，其中 1.2% 的眼睛出現濕狀，0.6% 的眼睛出現地理性萎縮。該隊列涵蓋了 4,926 名年齡在 43 至 86 歲之間的人。在弗雷明漢眼科研究中發現了類似的患病率數據，該研究報告稱，52 歲及以上人群的濕性 ARMD 患病率為 1.5%。年齡相關性黃斑變性的患病率在 75 歲以上人群中急劇增加。

值得關注的主要公司

諾華公司：

概述 Novartis AG 是一家瑞士跨國製藥公司，總部位於瑞士巴塞爾。我們通過兩個部門運作。它分為兩個部門：Innovative Pharmaceuticals 和 Sandoz。創新藥物部門由兩個業務部門組成，諾華製藥，包括諾華基因治療和諾華腫瘤學，將創新的專利藥物商業化，以改善患者和醫療保健專業人員的健康。我在這裡。作為仿製藥和生物仿製藥的全球領導者，山德士正在開拓新方法，以增加世界各地人們獲得優質藥物的機會。

產品組合：Beovu (brolucizumab) - Beovu (brolucizumab) 是歐洲唯一獲批的用於濕性 AMD 的抗 VEGF 治療藥物。

本報告提供了近 45+ 個市場數據表、40+ 個圖表和 180 頁有關全球老年性黃斑變性市場的信息。待辦。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
  • 驅動程序
    • 全球與年齡相關的眼病和老齡化人口增加
    • 技術進步
    • 推出用於治療老年性黃斑變性 (AMD) 的新產品
  • 約束因素
    • 可供選擇的治療方法
    • 昂貴的醫療費用
  • 商機
  • 影響分析

第5章產業要素

  • 波特的五種力量
  • 監管機構分析
  • 供應鏈分析
  • 報銷分析
  • 管道分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • 對 COVID-19 市場的分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按藥物類型

  • Lucentis
  • 艾莉亞
  • 阿瓦斯汀
  • 其他

第 8 章按疾病類型

  • 乾性 AMD
  • 濕式 AMD

第 9 章治療

  • 抗血管內皮細胞生長因子注射療法
  • 光動力療法
  • 激光手術
  • 抗生素滴注
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • 諾華
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Bayer
  • Roche
  • Bausch & Lomb
  • Allergan
  • Iconic Therapeutics
  • Neurotech Pharmaceuticals
  • Regeneron Pharmaceuticals Inc
  • Alcon
  • Santen Pharmaceutical

第13章 全球年齡相關性黃斑變性市場-DataM

簡介目錄
Product Code: DMPH114

Market Overview

Age-Related Macular Degeneration Market size was valued US$ 9.84 billion in 2021 and is estimated to reach US$ YY billion by 2029, growing at a CAGR of 6.90% during the forecast period (2022-2029).

Age-related macular degeneration comprises products that treat acute and chronic wounds, such as ulcers, burns, and post-operative wounds. The products, such as film and foam dressings, hydrogels, alginates, and hydrocolloids, keep the damage hydrated to encourage healing without occluding the wound. The market offers solutions to patients suffering from chronic wounds by providing them with readily reachable and priced products that can be used at their convenience. The Age-Related Macular Degeneration management market report also covers various competing technologies, such as advanced wound dressing technologies, harmful pressure wound therapies (NPWT), biologics/bioactive products, and hyperbaric oxygen therapy devices.

Market Dynamics

The growth of the market is majorly driven by growing age-related eye diseases across the world, growing aged population, advancements in technology, and reimbursement benefits for treatment are the major factors driving the growth of this market

Growing age-related eye diseases across the world, growing aged population are expected to drive market growth

According to the WHO, globally, around 196 million people were affected by age-related macular degeneration in 2020, including over 10.4 million moderate-to-severe vision impairment cases. Moreover, the United Nations Department of Economic and Social Affairs data revealed that the aged population of 65 years and above was around 727 million in 2020. However, by 2050, the geriatric population will increase approximately 2 million. Only a few drugs, mainly anti-VEGFs, are currently approved to treat age-related macular degeneration. Anti-VEGF drugs require repetitive and inconvenient intraocular injections, which increases the burden and results in non-adherence to treatment. To overcome this challenge, key players are developing longer-acting anti-VEGFs and vitreous implants that facilitate the sustained delivery of drugs. The introduction of long-acting anti-VEGF, such as Beovu and Vabysmo, is expected to boost the market growth over the forecast period.

The high cost associated with the treatment is one of the major factors hindering the growth of the market

The main restrain of this market is the treatment cost. Each injection costs up to $775.3, and most patients require around eight injections annually. However, in several studies, a third very similar drug, bevacizumab (Avastin), which costs only $27.14 per injection, had similar efficacy to ranibizumab and aflibercep IVAN trial (funded by the UK Department of Health). As a result, bevacizumab is widely used in other countries, including the USA and Australia, for AMD and in the UK for other conditions that cause neovascularisation (e.g., diabetic retinopathy). However, apart from not being licensed for AMD in the UK, this cheaper alternative is not used widely in the NHS for this common condition.

COVID-19 Impact Analysis

During the early phase of the COVID-19 pandemic, the market was negatively impacted due to missed or delays in follow-up for AMD treatment leading to non-adherence to medications. For example, in July 2020, Hoffman Roche witnessed low growth in the sale of its AMD drug Lucentis to USD 401 million in the second quarter over the same period in the previous year.

Global Age-Related Macular Degeneration Market - Industry Analysis

The global age-related macular degeneration market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, reimbursement analysis, supply chain analysis, pricing analysis, technological advancements etc.

Segment Analysis

Wet AMD segment is expected to hold the largest market share in global age-related macular degeneration market

Wet AMD cases account for more than 10-15% of macular degeneration-related vision loss cases worldwide. Lucentis, Eylea, and Beovu are effective drugs for treating wet age-related macular degeneration. Novartis' Beovu, a long-acting anti-VEGF, was approved by the U.S. FDA in October 2019. Although, the unfavourable side effects of this drug, such as retinal vasculitis, will limit its broader uptake.

Furthermore, in September 2021, Biogen Inc. and Samsung Bioepis Co., Ltd. obtained U.S. FDA approval for their biosimilar version of Lucentis under the brand name of BYOOVIZ for treating wet AMD, myopic choroidal neovascularization, and retinal vein occlusion. However, the product was launched in the U.S. on June 2022, owing to applicable supplementary protection certificates. In addition, the product received approval in EU countries, including the U.K., in August 2021.

Geographical Analysis

North America region holds the largest market share in the global age-related macular degeneration market

North America dominated the global age-related macular degeneration market and is expected to retain its position during the forecast period. According to the American Academy of Ophthalmology, around 15 million North Americans live with AMD. Moreover, the prevalence of advanced ARMD in the Beaver Dam Eye Study was 1.6%, with the exudative form being present in one eye 1.2% of the time, and geographic atrophy in one eye 0.6% of the time. This population represented 4,926 people between the ages of 43 to 86 years of age. Similar prevalence data was noted in the Framingham Eye Study, which reported a prevalence of exudative ARMD in those older than 52 years of age of 1.5%. The prevalence of age-related macular degeneration sharply increases in those 75 years or older.

Competitive Landscape

The age-related macular degeneration market is moderately competitive. The key players contributing to the global market's growth include Bayer, Novartis, Roche, Bausch & Lomb, Allergan, Iconic Therapeutics, Neurotech Pharmaceuticals, Regeneron Pharmaceuticals Inc., Alcon, Santen Pharmaceutical. For instance, in June 2021, Mosaic Biosciences and Ocular Therapeutix entered into a research collaboration for the development of a drug to treat patients with dry age-related macular degeneration.

Key Companies to Watch

Novartis AG:

Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It operates business through two divisions: Innovative medicine, Sandoz. Made up of two business units - Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology - our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.

Product Portfolio: Beovu (brolucizumab) - Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD.

The global age-related macular degeneration market report would provide an access to an approx. 45+ market data table,, 40+ figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Growing age-related eye diseases across the world, growing aged population
    • 4.2.2. Advancements in technology
    • 4.2.3. The introduction of new products for the treatment of age-related macular degeneration (AMD)
  • 4.3. Restraints
    • 4.3.1. Availability of alternative treatment options
    • 4.3.2. High cost of treatments
  • 4.4. Opportunities
  • 4.5. Impact Analysis

5. Industry Factors

  • 5.1. Porter's Five Forces
  • 5.2. Regulator Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Reimbursement Analysis
  • 5.5. Pipeline analysis
  • 5.6. Pricing Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Lucentis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Eylea
  • 7.4. Avastin
  • 7.5. Others

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.1.2. Market Attractiveness Index, By Disease Type
  • 8.2. Dry AMD*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Wet AMD

9. By Treatment Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.1.2. Market Attractiveness Index, By Treatment Type
  • 9.2. Injecting Anti-vascular endothelial growth factor*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Photodynamic therapy
  • 9.4. Laser surgery
  • 9.5. Antibiotic drops
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. The U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East & Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Novartis
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bayer
  • 12.3. Roche
  • 12.4. Bausch & Lomb
  • 12.5. Allergan
  • 12.6. Iconic Therapeutics
  • 12.7. Neurotech Pharmaceuticals
  • 12.8. Regeneron Pharmaceuticals Inc
  • 12.9. Alcon
  • 12.10 Santen Pharmaceutical

LIST NOT EXHAUSTIVE

13. Global Age-Related Macular Degeneration Market - DataM

  • 13.1. Appendix
  • 13.2. About Us
  • 13.3. Contact Us